The first of nearly three million doses of the first Covid-19 vaccine were packed in dry ice and put on trucks at a Pfizer plant in Kalamazoo, Mich., on Sunday morning, destined for hundreds of distribution centers in all 50 states, the most ambitious vaccination campaign in American history.
More than 15 million people in the U.S. have had confirmed coronavirus infections and more than 280,000 have died of COVID-19. Tens of thousands of new cases are reported daily nationwide. In the graphics (attached) , explore the trends in your state.
The United States will buy 100 million additional shots of Moderna’s Covid-19 vaccine — doubling its initial order of the vaccine, which the FDA is expected to authorize later this month.
With new coronavirus cases and deaths continuing to emerge at record levels, the United States is poised to begin a lengthy vaccination campaign.
The first shipments of Pfizer-BioNTech and Moderna vaccine will not be enough to inoculate even just the medical workers and nursing home residents at the top of the waiting list. But after federal regulators granted emergency authorization for the Pfizer vaccine, millions of doses were expected to be shipped across the country, a small but tangible step toward ending the pandemic.
By design, the vaccine rollout will be a patchwork. Though federal regulators are responsible for deciding when a vaccine can be safely used, it is largely up to the states to determine how to deploy the doses they receive. Recipients of both vaccines will need two doses administered weeks apart. Distribution is meant to be based on adult population estimates.
The Food and Drug Administration authorized Pfizer’s Covid-19 vaccine for emergency use on Friday, clearing the way for millions of highly vulnerable people to begin receiving the vaccine within days.
The authorization was signed by the agency’s chief scientist on Friday evening, according to three people with knowledge of the decision who spoke on condition of anonymity because they were not authorized to discuss it.
UK and Russian scientists are teaming up to trial a combination of the Oxford-AstraZeneca and Sputnik V vaccines to see if protection against Covid-19 can be improved.
Mixing two similar vaccines could lead to a better immune response in people.
Recent Comments